Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

PURPOSE: To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in patients with advanced urothelial bladder cancer (UBC). METHODS: A phase 1/2 multicenter, open-label...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Massard, Christophe, Gordon, Michael S., Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A., Luke, Jason, Curiel, Tyler J., Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E., O’Donnell, Peter H., Drakaki, Alexandra, Tan, Winston, Kurland, John F., Rebelatto, Marlon C., Jin, Xiaoping, Blake-Haskins, John A., Gupta, Ashok, Segal, Neil H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569690/
https://ncbi.nlm.nih.gov/pubmed/27269937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.9761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados